



Pharmacologic Agents for Treatment of Type 2 Diabetes

SCAN Formulary Drugs

Medication	2022 Formulary		2023 Formulary		Dosing & Administration	Risk for Drug- Drug Interactions*	Adverse Drug Reactions
	Tier	UM	Tier	UM			
Biguanides							
<i>metformin tabs</i>	1		1		500 – 850 mg QD - TID	Neutral	Nausea/ vomiting, GI upset, metallic taste, diarrhea, flatulence, lactic acidosis (rare)
<i>metformin er uncoated tabs</i> 500 mg & 750 mg	1		1		500 – 2000 mg daily		Nausea/ vomiting, GI upset, diarrhea, flatulence, lactic acidosis
Sulfonylureas							
<i>glimepiride</i>	1		1		1 – 8 mg daily	Moderate	Dizziness, headache, hypoglycemia, nausea, weight gain
<i>glipizide</i>	1		1		2.5 – 20 mg daily		Rash, diarrhea, dizziness, headache, diarrhea, hypoglycemia, nausea, weight gain
<i>glipizide er</i>	1		1		5 – 20 mg daily		Asthenia, headache, dizziness, rash, nausea, hypoglycemia, weight gain
<i>glipizide / metformin tabs</i>	1		1		2.5 / 500 mg BID	Moderate	Rash, diarrhea, dizziness, headache, nausea, flatulence, hypoglycemia, lactic acidosis
Thiazolidinediones & Thiazolidinedione Combination Agents							
<i>pioglitazone</i>	1		1		15 – 45 mg daily	Neutral	Anemia, edema, weight gain, headache, myalgia, bone fracture, heart failure
<i>pioglitazone / metformin</i>	2		2		15 / 500 mg – 45 / 1500mg daily		Rash, diarrhea, dizziness, headache, nausea, flatulence, hypoglycemia, lactic acidosis
<i>pioglitazone / glimepiride</i>	2	[QL]	2		15 / 500 mg – 45 / 2550 mg daily		Anemia, edema, weight gain, headache, myalgia, dizziness, hypoglycemia, nausea

Medication	2022 Formulary		2023 Formulary		Dosing & Administration	Risk for Drug- Drug Interactions*	Adverse Drug Reactions
	Tier	UM	Tier	UM			
Alpha-Glucosidase Inhibitor							
<i>acarbose</i>	2		2		25 – 100 mg TID Administered at the start of each meal to decrease postprandial glucose peaks	Neutral	Abdominal pain, diarrhea, flatulence, elevated serum transaminases
Meglitinides							
<i>nateglinide</i>	2		2		60 – 120 mg TID before meals	Moderate	Dizziness, arthralgia, diarrhea, hypoglycemia, weight gain, increased uric acid
<i>repaglinide</i>	2		2		0.5 – 4 mg TID before meals		Hypoglycemia, arthralgia, diarrhea, weight gain
DPPis (Dipeptidyl Peptidase-4 Inhibitors)							
JANUMET, JANUMET XR (<i>sitagliptin / metformin</i>)	3		3		100 / 2000 mg daily	Neutral	Abdominal pain, diarrhea, headache, nasopharyngitis, nausea, flatulence, lactic acidosis, pancreatitis
JANUVIA (<i>sitagliptin</i>)	3		3		100 mg daily	Neutral	Abdominal pain, diarrhea, headache, nasopharyngitis, nausea, URI, pancreatitis
JENTADUETO (<i>linagliptin / metformin</i>)	3		3		2.5 / 1000 mg BID	Neutral	Nasopharyngitis hypoglycemia, cough, diarrhea
JENTADUETO XR (<i>linagliptin / metformin</i>)	3		3		5 / 2000 mg daily	Neutral	Nasopharyngitis hypoglycemia, cough, diarrhea
TRADJENTA (<i>linagliptin</i>)	3		3		5 mg daily	Neutral	Hypoglycemia, diarrhea, cough, nasopharyngitis, arthralgia

Medication	2022 Formulary		2023 Formulary		Dosing & Administration	Risk for Drug- Drug Interactions*	Adverse Drug Reactions
	Tier	UM	Tier	UM			
TRIJARDY XR (<i>empagliflozin / linagliptin / metformin</i>)	3		3		25 / 5 / 2000 mg daily	Neutral	Upper respiratory tract infection, urinary tract infection, nasopharyngitis, diarrhea, constipation, headache, gastroenteritis
Insulins							
	Vial	Pen	Vial	Pen	Patient specific dosing applies	Neutral	Hypoglycemia, injection site reaction, lipodystrophy, hypokalemia
HUMALOG (<i>insulin lispro</i>)	3	3	3	3			
HUMALOG MIX 50/50, 75/25 (<i>insulin lispro / protamine</i>)	3	3	3	3			
HUMULIN 70/30 (<i>insulin human-regular / NPH</i>)	3	3	3	3			
HUMULIN N (<i>insulin NPH</i>)	3	3	3	3			
HUMULIN R (<i>insulin human-regular</i>)	3	-	3	-			
HUMULIN R U-500 (<i>insulin human-regular</i>)	3	3	3	3			
LANTUS (<i>insulin glargine</i>)	3	3	3	3			
LYUMJEV (<i>insulin lispro</i>)	3	3	3	3			
TOUJEO / TOUJEO MAX (<i>insulin glargine</i>)	-	3	-	3			
GIP/GLP-1 Agonist							
MOUNJARO (<i>tirzepatide</i>)	-	3	-	3	5 mg to 15 mg SC weekly	Neutral	Diarrhea, nausea, vomiting, headache, abdominal pain, constipation

Medication	2022 Formulary		2023 Formulary		Dosing & Administration	Risk for Drug- Drug Interactions*	Adverse Drug Reactions
	Tier	UM	Tier	UM			
Insulin/GLP-1 Agonist Combination							
SOLIQUA (<i>insulin glargine / lixisenatide</i>)	-	NF	-	3	15 units to 60 units SC daily	Neutral	Hypoglycemia, diarrhea, nausea, vomiting, headache, pancreatitis
GLP-1 Agonist (Glucagon-Like-Peptide-1)							
BYDUREON (<i>exenatide er</i>)	3		3		2 mg SC weekly	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
BYETTA (<i>exenatide</i>)	3		3		5 – 10 mcg SC BID	Neutral	
OZEMPIC (<i>semaglutide</i>)	3		3		0.5 – 1 mg weekly	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
RYBELSUS (<i>semaglutide</i>)	3		3		0.5 – 1 mg weekly	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
TRULICITY (<i>dulaglutide</i>)	3		3		0.75 – 1.5 mg weekly	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
VICTOZA (<i>liraglutide</i>)	3		3		0.6 mg – 1.8mg SC daily	Neutral	Diarrhea, nausea, vomiting, constipation, headache, pancreatitis
Amylinomimetic							
SYMLIN PEN (<i>pramlintide</i>)	5		5		60 mcg – 120 mcg SC prior to main meals	Neutral	Nausea, anorexia, dizziness, fatigue

Medication	2022 Formulary		2023 Formulary		Dosing & Administration	Risk for Drug- Drug Interactions*	Adverse Drug Reactions
	Tier	UM	Tier	UM			
SGLT2 Inhibitor (Sodium-Glucose Cotransporter 2)							
FARXIGA (<i>dapagliflozin</i>)	3		3		5 – 10 mg daily	Neutral	Genital mycotic infections, nasopharyngitis, UTI, back pain, increased urination, nausea
GLYXAMBI (<i>empagliflozin / linagliptin</i>)	3		3		10 / 5 – 25 / 5 mg daily	Neutral	Urinary tract infections, nasopharyngitis, hypoglycemia, cough, diarrhea, upper respiratory tract infections
INVOKAMET (<i>canagliflozin / metformin</i>)	3		NF		50 / 500 – 150 / 1000 mg BID	Neutral	Abdominal discomfort, constipation, diarrhea, flatulence, increased thirst, indigestion, N/V, asthenia, headache, UTI, polyuria pruritis
INVOKAMET XR (<i>canagliflozin/ metformin</i>)	3		NF		100 / 1000 – 300 / 2000 mg daily	Neutral	Abdominal discomfort, constipation, diarrhea, flatulence, increased thirst, indigestion, N/V, asthenia, headache, UTI, polyuria pruritis
INVOKANA (<i>canagliflozin</i>)	3		NF		100 – 300 mg daily	Neutral	Genital mycotic infections, UTI, thirst, increased urination, nausea
JARDIANCE (<i>empagliflozin</i>)	3		3		10 – 25 mg daily	Neutral	Urinary tract infections and female genital mycotic infections
SYNJARDY (<i>empagliflozin / metformin</i>)	3		3		12.5 / 1000 mg BID	Neutral	Urinary tract infections, female genital mycotic infections, diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache
SYNJARDY XR (<i>empagliflozin / metformin</i>)	3		3		25 / 2000 mg daily	Neutral	Urinary tract infections, female genital mycotic infections, diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache
XIGDUO XR (<i>dapagliflozin / metformin</i>)	3		3		5 / 500 – 10 / 2000 mg daily	Neutral	Low vitamin-B12, diarrhea, headache, UTI, genital mycotic infection, nasopharyngitis

Medication	2022 Formulary		2023 Formulary		Dosing & Administration	Risk for Drug- Drug Interactions*	Adverse Drug Reactions
	Tier	UM	Tier	UM			
Mineralcorticoid Receptor Antagonist							
KERENDIA <i>(finerenone)</i>	NF		3		20 mg daily	Neutral	Hypotension, hyponatremia, hyperkalemia

Brand-name drugs are capitalized and generic drugs are listed in the lower-case italics.

[NF] = Non-formulary

[QL] = Quantity Limit

* 2019 AACE/ACE Consensus Statement

Diabetes Guidelines References

SCAN Health Plan Diabetes Guidelines adapted from:

- American Diabetes Association; Standards of Medical Care in Diabetes-2022: Diabetes Care January 2022 vol. 45 no. Supplement 1 S1-S2 (Accessed 9/6/2022)
- Summary of Revisions: Standards of Medical Care in Diabetes 2022. Diabetes Care 2022;45(Suppl. 1):S4–S7 | <https://doi.org/10.2337/dc22-SREV>
- Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. Endocrine Practice. (2020, January). Vol. 26, No. 1, pp. 107-139.
- Drug Facts & Comparisons. (2022, Sept). Retrieved from www.online.factsandcomparisons.com. Wolters Kluwer Health: Deventer, The Netherlands.
- Epocrates Online (2022, Sept). Retrieved from: <http://online.epocrates.com>. Epocrates, Inc.: San Mateo, California.
- Reuben, D. B., Herr, K. A., Pacala, J. T., Pollock, B. G., Potter, J. F., & Semla, T. P. (2015). Geriatrics at your fingertips. 17th ed. (Based on AGS Guidelines.)
- Online Lexicomp (09/2022): 1100 Terex Road, Hudson, OH 44236